Study of H021 tablets for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This study tests an experimental pill, H021, for people with moderate to severe Crohn's disease. It aims to see if H021 can reduce inflammation and improve symptoms. Participants will take the pill or a placebo, and the study will monitor how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have been diagnosed with Crohn's disease for at least 12 weeks.
- Your Crohn's must be moderately to severely active, as shown by a recent colonoscopy and symptom score.
- You must have tried at least one standard treatment (like steroids, immunosuppressants, or biologics) and it didn't work or you couldn't tolerate it.
- You must be able to have a colonoscopy and follow the study procedures, including daily symptom diaries.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests an experimental oral medication, HRS-7085, for people with moderate to severe ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if it can help control inflammation and symptoms like diarrhea and rectal bleeding.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.